| Identification | Back Directory | [Name]
P-[[4-[[4-Hydroxy-3-(phenylmethyl)phenyl]methyl]-3,5-dimethylphenoxy]methyl]phosphonic acid | [CAS]
852949-30-5 | [Synonyms]
VK-0214
P-[[4-[[4-Hydroxy-3-(phenylmethyl)phenyl]methyl]-3,5-dimethylphenoxy]methyl]phosphonic acid | [Molecular Formula]
C23H25O5P | [MOL File]
852949-30-5.mol | [Molecular Weight]
412.42 |
| Chemical Properties | Back Directory | [Boiling point ]
656.4±65.0 °C(Predicted) | [density ]
1.279±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted) | [form ]
Solid | [pka]
2.33±0.10(Predicted) | [color ]
White to pink |
| Hazard Information | Back Directory | [Uses]
VK-0214 is an agonist of the thyroid β receptor (TRβ). By activating the expression of ABCD2, it can reduce the accumulation of very long-chain fatty acids (VLCFAs) and further alleviate glioblastoma multiforme. VK-0214 has the effect of regulating fatty acid metabolism and can be used in the research of X-linked adrenoleukodystrophy (X-ALD)[1]. | [References]
[1] McGowan E, et al., Integrative Rare Disease Biomedical Profile based Network Supporting Drug Repurposing, a case study of Glioblastoma. Res Sq [Preprint]. 2023 Apr 18:rs.3.rs-2809689. DOI:10.21203/rs.3.rs-2809689/v1 |
|
| Company Name: |
Biorbyt Ltd.
|
| Tel: |
+44 (0)1223 859 353 |
| Website: |
http://www.biorbyt.com |
|